DBIC Ventures leads €1.6m seed investment in Clarity CX1
Summary
The solution was developed to fill a gap in the market for strategic sales and relationship management in sectors with notoriously complex and multi-layered customer engagement structures, including life sciences, manufacturing, and financial services. The company is targeting large multinationals operating in the US, Asia-Pacific, Europe, and the UK and is currently implementing CX1 with Stemline Therapeutics, a subsidiary of Menarini Group based in Italy. This growth, along with the investment, will support the creation of an additional 30 jobs – bringing Clarity CX1’s total headcount to more than 40, with the majority being based in Dublin. Chris Deren, CEO and founder, Clarity CX1, said: “Industries like pharmaceuticals, manufacturing and financial services have large voids in their CRM systems because of their extremely complex B2B sales cycles. We are providing users with the insights to make the best use of their time and therefore shorten the sales cycle and pursue more qualified opportunities.” “This significant investment underlines the founder’s impressive track record and the clear global market need for Clarity CX1,” said Colm O’Sullivan, partner, DBIC Ventures.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
